University of Alabama Medicine 2020 ASCO Highlights

 

University of Alabama Medicine 2020 ASCO Highlights
Avatar

2020 ASCO Update on Azacitidine Combinations in Frontline AML: What Is the Effect of Enasidenib + Aza on Complete Remission and Overall Response vs. Aza Monotherapy in IDH2-Mutant Disease?

By University of Alabama Medicine 2020 ASCO Highlights FEATURING Pankit Vachhani
By University of Alabama Medicine 2020 ASCO Highlights FEATURING Pankit Vachhani
67 views
September 9, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
Videos
16:36
University of Alabama Medicine 2020 ASCO Highlights

UAB ASCO 2020 Updates on HIF Inhibitors in Advanced RCC: Does Belzut…

Feat. A. Basu
13:07
University of Alabama Medicine 2020 ASCO Highlights

2020 ASCO Highlights on Newly Diagnosed MM: KRd vs. VRd - Are There …

Feat. S. Bal
05:17
University of Alabama Medicine 2020 ASCO Highlights

2020 ASCO Highlights on Advanced NSCLC: What Is the Clinical Benefit…

Feat. D. Das
06:56
University of Alabama Medicine 2020 ASCO Highlights

2020 ASCO Update on EGFR+ mNSCLC: Should We Incorporate Osimertinib …

Feat. D. Das
13:57
University of Alabama Medicine 2020 ASCO Highlights

2020 ASCO IMvigor 130 Bladder Cancer Updated Results: Does the Addit…

Feat. L. Nandagopal
09:38
University of Alabama Medicine 2020 ASCO Highlights

2020 ASCO Update on Advanced RCC: Are We Over-Treating Patients With…

Feat. L. Nandagopal
07:32
University of Alabama Medicine 2020 ASCO Highlights

2020 ASCO Update on Prostate Cancer: How Effective Is Enzalutamide i…

Feat. L. Nandagopal
15:11
University of Alabama Medicine 2020 ASCO Highlights

2020 ASCO Update on CP-CML: What Dose of Ponatinib Is Both Safe and …

Feat. P. Vachhani
10:41
University of Alabama Medicine 2020 ASCO Highlights

2020 ASCO Update on R/R AML: What AMG 330 Dosage Is Safe and Tolerab…

Feat. P. Vachhani
08:27
University of Alabama Medicine 2020 ASCO Highlights

2020 ASCO Update on Azacitidine Combinations in Frontline AML: Does …

Feat. P. Vachhani
07:10
University of Alabama Medicine 2020 ASCO Highlights

2020 ASCO Update on Azacitidine Combinations in AML: Are Aza/Ven/Ivo…

Feat. P. Vachhani
08:08
University of Alabama Medicine 2020 ASCO Highlights

2020 ASCO Update on Azacitidine Combinations in Frontline AML: What …

Feat. P. Vachhani
13:15
University of Alabama Medicine 2020 ASCO Highlights

2020 ASCO Update on Azacitidine Combinations in Myeloid Malignancies…

Feat. P. Vachhani
12:24
University of Alabama Medicine 2020 ASCO Highlights

2020 ASCO Update on mBC: Do Surgery and Radiation After Initial Syst…

Feat. E. Stringer-Reasor
11:17
University of Alabama Medicine 2020 ASCO Highlights

2020 ASCO Update on PIK3CA HR+ BC: Is Alpelisib Effective After CDK4…

Feat. E. Stringer-Reasor
14:19
University of Alabama Medicine 2020 ASCO Highlights

2020 ASCO Update on CAR-T in Lymphoma: First CD19/22 Dual Targeting …

Feat. A. Mehta